Q4 2025 Management View CEO Dikla Akselbrad described 2025 as “a pivotal year for PolyPid,” highlighting the completion of ...

Candidates appearing for the Civil Services Examination (CSE) 2026 will get an opportunity to make changes to their ...

PolyPid (NASDAQ:PYPD) said 2025 marked a “pivotal year” as the company completed its SHIELD II Phase 3 trial and moved D-PLEX100 into the final stages of regulatory preparation, while also advancing U ...

The Company is in AdvancedStagesof Commercial U.S. Partnership Discussions for D-PLEX₁₀₀Positive FDA Pre-NDA Feedback Supports Rolling NDA ...

In a fiery retort, Rabri Devi, the opposition face of Bihar, leveled strong allegations against the NDA, claiming they ...

KalVista Pharmaceuticals, Inc. is rated a Strong Buy due to EKTERLY's global launch and robust initial sales momentum. Read ...

In what has turned out to be an important day for the atopic dermatitis community, shares of two biopharma companies surged on phase II data showing statistically significant and sustained outcomes ...

On the heels of an NDA submission for brepocitinib in dermatomyositis, Priovant Therapeutics Inc. disclosed data showing the dual TYK2/JAK1 inhibitor surpassed expectations in a phase II study in ...

Roivant Sciences (NASDAQ:ROIV) executives highlighted new Phase II results for brepocitinib in cutaneous sarcoidosis, along ...

Q3 2025 earnings call: brepocitinib Phase II wins, Phase III plans, 2026 catalysts, $4.5B cash & Moderna trial—read key insights.

Veradermics completed enrolment for both Phase III VDPHL01 trials in male pattern hair loss, totalling over 1,000 participants.